Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27353798 | 1.00 | KMT2A (0.38) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL2552608 | 1.00 | KMT2A (0.38) | KMT2AMEN1GAANOS1NOS3 | |
| Hydrochloric Acid SCHEMBL27995082 | 0.98 | KMT2A (0.37) | KMT2AMEN1GAANOS1NOS3 | |
| Hydrochloric Acid SCHEMBL27995084 | 0.98 | KMT2A (0.37) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27747509 | 0.91 | NOS1 (0.36) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL3693114 | 0.83 | CA12 (0.38) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL3693112 | 0.83 | CA12 (0.38) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27930493 | 0.83 | GABRR1 (0.43) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27798380 | 0.83 | DGAT1 (0.33) | KMT2ANOS1NOS3NOS2LMNA | |
| SCHEMBL27657696 | 0.83 | GABRR1 (0.43) | KMT2AMEN1GAANOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104024258-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| CN-101889011-B | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3- carboxylic acid amides | BOEHRINGER INGELHEIM INT | 2014-05-28 | — | — | CN | disclosed |
| CN-102448960-A | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INT | 2012-05-09 | — | — | CN | disclosed |
| CN-102143944-A | Organic compounds | NABRIVA THERAPEUTICS AG | 2011-08-03 | — | — | CN | disclosed |
| CN-101889011-A | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3- carboxylic acid amides | BOEHRINGER INGELHEIM INT | 2010-11-17 | — | — | CN | disclosed |
| CN-1753891-A | Ccr-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-03-29 | — | — | CN | disclosed |
| CN-1575283-A | Piperazine derivatives having CCR1 receptor antagonist activity | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| CN-1529699-A | Novel sulfonic acid derivatives | �Ʒ� | 2004-09-15 | — | — | CN | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| CN-1450999-A | Novel piperazine derivatives | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | KMT2A 3604/4885MEN1 2967/4885GAA 1306/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | KMT2A 4143/4885MEN1 2295/4885GAA 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.